All In Biotech

Drug Trial Radar · NCT03168334

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-123 Lotion and IDP-123 Vehicle Lotion in the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Apr 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 801 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

801

Actual

Start

Jul 11, 2017

Primary completion

Jul 24, 2018

Study completion Jul 24, 2018

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
May 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.

Conditions

  • Acne Vulgaris

Interventions

  • IDP-123 LotionDrug

    Tazarotene 0.045% Lotion

  • IDP-123 Vehicle LotionDrug

    Vehicle Lotion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change in Mean Lesion Counts at Week 12Time frame: Baseline to Week 12
  2. Percentage of Subjects Who Had at Least a 2-grade Reduction From Baseline at Week 12 in the Evaluator's Global Severity Score (EGSS) and Had an EGSS at Week 12 That Equated to "Clear" or "Almost Clear"Time frame: Baseline to Week 12

Locations

45 sites in 2 countries. Site status is shown where the registry gives one.

  • Valeant Site 41

    Mobile, Alabama

  • Valeant Site 22

    Rogers, Arkansas

  • Valeant Site 34

    Carlsbad, California

  • Valeant Site 12

    Fremont, California

  • Valeant Site 06

    San Diego, California

  • Valeant Site 13

    San Diego, California

  • Valeant Site 31

    San Diego, California

  • Valeant Site 36

    Santa Ana, California

  • Valeant Site 25

    Denver, Colorado

  • Valeant Site 05

    Boynton Beach, Florida

  • Valeant Site 29

    Clearwater, Florida

  • Valeant Site 38

    Jupiter, Florida

  • Valeant Site 02

    Miami, Florida

  • Valeant Site 26

    West Palm Beach, Florida

  • Valeant Site 44

    Snellville, Georgia

  • Valeant Site 32

    Louisville, Kentucky

  • Valeant Site 19

    Rockville, Maryland

  • Valeant Site 08

    Bay City, Michigan

  • Valeant Site 30

    Clarkston, Michigan

  • Valeant Site 37

    Clinton Township, Michigan

  • Valeant Site 20

    Fort Gratiot, Michigan

  • Valeant Site 24

    Fridley, Minnesota

  • Valeant Site 03

    Morristown, New Jersey

  • Valeant Site 42

    Albuquerque, New Mexico

  • Valeant Site 10

    New York, New York

  • Valeant Site 43

    Rochester, New York

  • Valeant Site 33

    Stony Brook, New York

  • Valeant Site 11

    Oklahoma City, Oklahoma

  • Valeant Site 28

    Broomall, Pennsylvania

  • Valeant Site 16

    Warwick, Rhode Island

  • Valeant Site 18

    Knoxville, Tennessee

  • Valeant Site 14

    Murfreesboro, Tennessee

  • Valeant Site 23

    College Station, Texas

  • Valeant Site 07

    Dallas, Texas

  • Valeant Site 27

    Pflugerville, Texas

  • Valeant Site 04

    San Antonio, Texas

  • Valeant Site 39

    Sugar Land, Texas

  • Valeant Site 09

    Layton, Utah

  • Valeant Site 15

    West Jordan, Utah

  • Valeant Site 21

    Charlottesville, Virginia

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.